Literature DB >> 8747869

Cytomegalovirus-associated transverse myelitis in a non-immunocompromised patient.

S M Baig1, M A Khan.   

Abstract

Cytomegalovirus-associated transverse myelitis (TM) is rare in immunocompetent patients. We report here the case of a 24-year-old woman who developed acute transverse myelitis with cerebrospinal fluid (CSF) findings, suggesting a central nervous system (CNS) infection, and a positive CMV serology.

Entities:  

Mesh：

Year:  1995        PMID： 8747869     DOI： 10.1016/0022-510x(95)00270-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  CNS manifestations of cytomegalovirus infections: diagnosis and treatment.

Authors:  Matthias Maschke; Oliver Kastrup; Hans-Christoph Diener
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Cytomegalovirus-associated transverse myelitis in a non-immunocompromised patient.

Authors:  M Giobbia; A Carniato; P G Scotton; G C Marchiori; A Vaglia
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

3.  Cytomegalovirus associated transverse myelitis in an immunocompetent host with DNA detection in cerebrospinal fluid; a case report.

Authors:  Suneth Karunarathne; Dumitha Govindapala; Yapa Udayakumara; Harshini Fernando
Journal:  BMC Res Notes       Date:  2012-07-20

4.  Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.

Authors:  Amer Awad; Olaf Stüve
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

5.  Cytomegalovirus-associated encephalomyelitis in an immunocompetent adult: a two-stage attack of direct viral and delayed immune-mediated invasions. case report.

Authors:  Kensuke Daida; Yuta Ishiguro; Hiroto Eguchi; Yutaka Machida; Nobutaka Hattori; Hideto Miwa
Journal:  BMC Neurol       Date:  2016-11-17       Impact factor: 2.474

Review 6.  Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.

Authors:  T Bergström
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.